Zevra Therapeutics Inc (ZVRA)
8.66
+0.26
(+3.10%)
USD |
NASDAQ |
Nov 04, 13:00
Zevra Therapeutics Total Liabilities (Quarterly): 111.93M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 111.93M |
| March 31, 2024 | 102.46M |
| December 31, 2023 | 110.46M |
| September 30, 2023 | 71.51M |
| June 30, 2023 | 37.02M |
| March 31, 2023 | 35.19M |
| December 31, 2022 | 40.22M |
| September 30, 2022 | 25.76M |
| June 30, 2022 | 25.02M |
| March 31, 2022 | 4.207M |
| December 31, 2021 | 5.823M |
| September 30, 2021 | 5.449M |
| June 30, 2021 | 8.134M |
| March 31, 2021 | 6.184M |
| December 31, 2020 | 77.62M |
| September 30, 2020 | 73.53M |
| June 30, 2020 | 75.19M |
| March 31, 2020 | 77.56M |
| December 31, 2019 | 84.96M |
| September 30, 2019 | 83.51M |
| Date | Value |
|---|---|
| June 30, 2019 | 94.56M |
| March 31, 2019 | 94.70M |
| December 31, 2018 | 93.31M |
| September 30, 2018 | 114.08M |
| June 30, 2018 | 117.54M |
| March 31, 2018 | 122.33M |
| December 31, 2017 | 109.97M |
| September 30, 2017 | 107.41M |
| June 30, 2017 | 108.32M |
| March 31, 2017 | 109.57M |
| December 31, 2016 | 103.58M |
| September 30, 2016 | 104.35M |
| June 30, 2016 | 104.30M |
| March 31, 2016 | 123.42M |
| December 31, 2015 | 64.71M |
| September 30, 2015 | 67.16M |
| June 30, 2015 | 63.08M |
| March 31, 2015 | 68.47M |
| December 31, 2014 | 62.22M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.207M
Minimum
Mar 2022
111.93M
Maximum
Jun 2024
51.49M
Average
40.22M
Median
Dec 2022
Total Liabilities (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 108.86M |
| BioCardia Inc | 4.851M |
| Xeris Biopharma Holdings Inc | 351.02M |
| Crinetics Pharmaceuticals Inc | 104.77M |
| Instil Bio Inc | 99.30M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 144.41M |
| Shareholders Equity (Quarterly) | 32.48M |
| Debt to Equity Ratio | 1.796 |
| Current Ratio | 2.000 |
| Net Debt Paydown Yield | -4.41% |